Intravenous administration of the anti–vascular endothelial growth factor treatment bevacizumab at high doses can result in serious, systemic adverse events (AEs). Additionally, tumors can become resistant to therapy and adopt a more invasive growth pattern. Thus, delivering bevacizumab for the treatment of cancer at a lower dose in a manner that avoids systemic AEs is necessary.
Intravenous administration of the anti—vascular endothelial growth factor treatment bevacizumab at high doses can result in serious, systemic adverse events (AEs). Additionally, tumors can become resistant to therapy and adopt a more invasive growth pattern. Thus, delivering bevacizumab for the treatment of cancer at a lower dose in a manner that avoids systemic AEs is necessary.
A recent study, published in OncoTargets and Therapy, sought to evaluate the therapeutic effect of intratumoral low-dose bevacizumab versus high-dose treatment in glioma-bearing animals, and found that administering bevacizumab by intratumoral injection might be an effective protocol for treating gliomas by regulating the expression of inflammation and invasion-related factors and inhibiting cancer stem cells.
In mice implanted with glioma cells, researchers found that bevacizumab delivered by intratumoral injection or systemic (intravenous) administration was effective, but intratumoral injection was more efficient; the bioluminescence imaging signal used to assess tumor growth in mice treated intratumorally was less intense than it was in those treated with intravenous therapy.
Injected bevacizumab was also associated with increased survival; mice that received intratumoral injections had a median survival of 40 days versus 27 days in the intravenous therapy group.
The density of tumor blood vessels was also reduced in mice who received injections, as were invasive factors of tumors and cancer stem cells, versus mice who received systemic therapy. However, inflammatory factors of tumors increased in the injection group; cold-inducible RNA-binding protein, which mediates brain injury, was significantly increased in the injected group versus the systemic therapy group.
The authors concluded that localized delivery of bevacizumab was more effective in reducing tumor size and cell infiltration versus intravenous delivery, and could be considered an alternative to intravenous therapy. While more research will be necessary, the identification of this possibility serves as a first step, write the authors, to a novel delivery method that could overcome the AEs associated with systemic therapy.
Reference
Liu YX, L WJ, Zhang HR, Zhang ZW. Delivery of bevacizumab by intracranial injection: assessment in glioma model. Onco Targets Ther. 2018;11:2673-2683. doi: 10.2147/OTT.S159913.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.